- In late June 2026, InnovAge Holding Corp. was removed from several Russell value indices, including the Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, and Small Cap Comp Value, following the annual index reconstitution.
- This broad index removal can matter for InnovAge’s investor base because funds tracking these benchmarks may adjust their holdings, potentially altering liquidity and ownership over time.
- We’ll now examine how InnovAge’s removal from multiple Russell value indices may influence its investment narrative and longer-term investor appeal.
The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
InnovAge Holding Investment Narrative Recap
To own InnovAge, you need to believe its PACE-focused, value-based care model can someday translate growing revenue into sustainable profitability, despite ongoing losses and rising operating costs. The recent removal from multiple Russell value indices mainly affects technical ownership and liquidity rather than the core near term business catalysts or the central risks around cost inflation, regulatory exposure, and execution on new center expansion.
The most relevant recent announcement here is InnovAge’s Q3 FY2026 update, where management raised full year revenue guidance to US$950 million to US$975 million while reporting a wider net loss of US$29.46 million. Taken together with the index removals, this combination of higher expected revenue and persistent losses keeps the focus squarely on whether InnovAge can eventually align cost growth, de novo center ramp up, and compliance spending with its top line trajectory.
Yet behind the index changes and upbeat revenue guidance, investors should still be aware of the risk that persistently high cost growth could...
Read the full narrative on InnovAge Holding (it's free!)
InnovAge Holding’s narrative projects $1.2 billion revenue and $165.3 million earnings by 2029.
Uncover how InnovAge Holding's forecasts yield a $7.00 fair value, a 42% downside to its current price.
Exploring Other Perspectives
Two Simply Wall St Community fair value estimates range from US$7 to US$29.57 per share, underscoring how far apart individual views can be. You should weigh those against the concern that InnovAge’s rising cost of care and de novo losses could pressure margins for longer than expected, and consider how that might influence the company’s ability to improve performance over time.
Explore 2 other fair value estimates on InnovAge Holding - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your InnovAge Holding research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free InnovAge Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnovAge Holding's overall financial health at a glance.
Looking For Alternative Opportunities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com